Thermo Fisher Scientific Inc. (TMO) Position Lifted by Mastrapasqua Asset Management Inc.

Mastrapasqua Asset Management Inc. boosted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.9% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 38,521 shares of the medical research company’s stock after buying an additional 338 shares during the period. Thermo Fisher Scientific makes up about 1.5% of Mastrapasqua Asset Management Inc.’s holdings, making the stock its 21st biggest position. Mastrapasqua Asset Management Inc.’s holdings in Thermo Fisher Scientific were worth $7,288,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of the stock. Chicago Partners Investment Group LLC purchased a new position in Thermo Fisher Scientific in the second quarter valued at about $108,000. Shine Investment Advisory Services Inc. purchased a new position in Thermo Fisher Scientific in the second quarter valued at about $113,000. Ropes Wealth Advisors LLC grew its stake in Thermo Fisher Scientific by 15.8% in the second quarter. Ropes Wealth Advisors LLC now owns 710 shares of the medical research company’s stock valued at $124,000 after purchasing an additional 97 shares in the last quarter. Atlantic Trust LLC purchased a new position in Thermo Fisher Scientific in the second quarter valued at about $138,000. Finally, Grove Bank & Trust grew its stake in Thermo Fisher Scientific by 19.9% in the second quarter. Grove Bank & Trust now owns 860 shares of the medical research company’s stock valued at $150,000 after purchasing an additional 143 shares in the last quarter. 86.05% of the stock is currently owned by hedge funds and other institutional investors.

In other news, CEO Marc N. Casper sold 50,000 shares of the company’s stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $191.74, for a total transaction of $9,587,000.00. Following the completion of the sale, the chief executive officer now owns 302,577 shares in the company, valued at approximately $58,016,113.98. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.49% of the company’s stock.

A number of brokerages have commented on TMO. Zacks Investment Research downgraded Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Monday, September 18th. Barclays restated an “overweight” rating and issued a $215.00 target price (up previously from $200.00) on shares of Thermo Fisher Scientific in a research note on Monday, September 25th. Argus restated a “buy” rating on shares of Thermo Fisher Scientific in a research note on Tuesday, August 22nd. They noted that the move was a valuation call. Jefferies Group restated a “hold” rating and issued a $195.00 target price on shares of Thermo Fisher Scientific in a research note on Thursday, September 28th. Finally, Morgan Stanley restated an “overweight” rating and issued a $220.00 target price on shares of Thermo Fisher Scientific in a research note on Wednesday, September 6th. One research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $205.21.

Shares of Thermo Fisher Scientific Inc. (TMO) opened at $193.89 on Wednesday. The stock has a market capitalization of $77,620.68, a PE ratio of 21.27, a PEG ratio of 1.77 and a beta of 1.06. Thermo Fisher Scientific Inc. has a 52 week low of $139.88 and a 52 week high of $201.20. The company has a debt-to-equity ratio of 0.85, a quick ratio of 0.81 and a current ratio of 1.26.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, October 25th. The medical research company reported $2.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.24 by $0.07. The company had revenue of $5.12 billion during the quarter, compared to the consensus estimate of $5.03 billion. Thermo Fisher Scientific had a return on equity of 15.94% and a net margin of 11.73%. The firm’s revenue was up 13.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.03 EPS. research analysts expect that Thermo Fisher Scientific Inc. will post 9.36 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Monday, January 15th. Stockholders of record on Friday, December 15th will be paid a dividend of $0.15 per share. The ex-dividend date of this dividend is Thursday, December 14th. This represents a $0.60 annualized dividend and a dividend yield of 0.31%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.19%.

TRADEMARK VIOLATION NOTICE: This article was first reported by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The correct version of this article can be read at https://sportsperspectives.com/2017/12/20/thermo-fisher-scientific-inc-tmo-position-lifted-by-mastrapasqua-asset-management-inc.html.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply